on the analysis of viral load endpoints in hiv vaccine trials
Download
Skip this Video
Download Presentation
On the analysis of viral load endpoints in HIV vaccine trials

Loading in 2 Seconds...

play fullscreen
1 / 20

On the analysis of viral load endpoints in HIV vaccine trials - PowerPoint PPT Presentation


  • 347 Views
  • Uploaded on

On the analysis of viral load endpoints in HIV vaccine trials Michael Hudgens, Antje Hoering and Steve Self Fred Hutchinson Cancer Research Center Seattle, WA USA VE S effect on susceptibility Primary objective of preventive efficacy trials Possible Vaccine Effects

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'On the analysis of viral load endpoints in HIV vaccine trials' - Lucy


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
on the analysis of viral load endpoints in hiv vaccine trials

On the analysis of viral load endpoints in HIV vaccine trials

Michael Hudgens, Antje Hoering

and Steve Self

Fred Hutchinson Cancer Research Center Seattle, WA USA

possible vaccine effects
VES effect on susceptibility

Primary objective of preventive efficacy trials

Possible Vaccine Effects
  • VEP effect on disease progression
      • Requires long term follow-up of infected participants
  • VEI effect on infectiousness
      • Requires partner study or community randomization

Barcelona , 10 July 2002

question
How do we draw inference regarding VEP or VEI within the framework of a classic efficacy trial design?Question
  • Consider vaccine effects on surrogate markers of disease progression or secondary transmission
  • E.g., viral load, CD4+ count

Barcelona , 10 July 2002

challenges
2. Accounting for ARTChallenges

1. Viral load is a surrogate marker

3. Intent-to-treat vs. condition on infection

Barcelona , 10 July 2002

intent to treat
+ Preserves randomizationIntent-To-Treat
  • Compare VL in all participants according to randomization assignment

- Requires assigning VL to uninfected participants

- Potential loss of power

- Does not separate vaccine effects

Barcelona , 10 July 2002

condition on infection
Compare VL in infected participants only according to randomization assignmentCondition on Infection
  • Subject to selection bias since comparing two groups that are defined by a post - randomization event, infection
  • Most relevant selective mechanism: VES
    • Participant immune system
    • Infecting viral strain

Barcelona , 10 July 2002

selection bias example i
Suppose vaccine protects recipients with stronger immune systemsSelection bias – Example I
  • Infected vaccinees have weaker immune systems on average than infected controls
  • Vaccine may appear to enhance VL

due solely to selection bias

Barcelona , 10 July 2002

selection bias example ii
Suppose vaccine protects recipients against relatively innocuous strainsSelection bias – Example II
  • Vaccinees infected by more virulent strains on average than infected controls
  • Vaccine appears to enhanceVL

due solely to selection bias

Barcelona , 10 July 2002

testing for ve on vl
Define difference in mean VL:

=mean VLV – mean VLC

Testing for VE on VL
  • Due to selection bias replace

H0:   0

by

H0 :  VL

where threshold VL is determined by amount

of selection

Barcelona , 10 July 2002

selection bias model
Assume:

Integrity of randomization, blinding

VES0

Vaccine has no effect on VL (null hypothesis)

Selection bias - model
  • Then:
      • VL distribution for infected vaccinees can be represented as a rescaled subdistribution of the VL distribution for infected controls

Barcelona , 10 July 2002

testing for ve on vl13
Assume extreme selection bias modelTesting for VE on VL
  • Then testing

H0 : VL

is simply testing for a difference in means greater than VL between two groups

  • E.g., t-test
  • Bootstrap procedure employed to assess significance

Barcelona , 10 July 2002

simulated efficacy trial
VES: 0%, 30%, 50%, 80%Simulated Efficacy Trial
  • Randomized, placebo control: NV=NC=1000
  • Number of infected controls: nC=90
  • Three scenarios
      • H0: =VL
      • HA: =VL + 1/3
      • HA: =VL + 1/2
  • VL distribution: =4.5, 2=0.4

Barcelona , 10 July 2002

slide15
Simulation Results - Power

Barcelona , 10 July 2002

simulation results power
Intent-to-treat vs Conditional

Test for difference in mean VL using bootstrap

VES=0

Simulation results - Power

Barcelona , 10 July 2002

conclusions
Comparing post-infection endpoints (VL, CD4+) in infected vaccinees vs infected controls subject to selection biasConclusions
  • Statistical methods have been developed to test for vaccine effects on post-infection endpoints beyond possible selection bias
  • Adequate power remains to detect clinically meaningful effects

Barcelona , 10 July 2002

other applications
Dichotomous outcomes

Disease/death

Secondary transmission

Other Applications
  • Monkey studies
  • Mother to child transmission studies
      • Condition on survival of the child beyond birth

Barcelona , 10 July 2002

references
Hudgens, Hoering, and Self. On the analysis of viral load endpoints in HIV vaccine trials. Statistics in Medicine, In press.

Gilbert and Bosch. Sensitivity analysis for the assessment of vaccine effects on viral load in HIV vaccine trials. Submitted.

References

Barcelona , 10 July 2002

acknowledgments
Steve Self, FHCRC, Seattle

Antje Hoering, Insightful Corp, Seattle

Peter Gilbert, FHCRC, Seattle

M. Elizabeth Halloran, Emory Univeristy, Atlanta

NIAID

Acknowledgments

Barcelona , 10 July 2002

ad